A1LN34.SA

Alnylam Pharmaceuticals, Inc. · Healthcare · Biotechnology

Earnings call summary →

—

Loading quote…

Highlights

Market Cap

$38.46B

PE Ratio

384.74

EV to Ebitda

—

Earnings Yield

0.00%

Revenue (TTM)

$853.1M

Net Income (TTM)

$100.0M

Revenue (Annual YoY Growth)

—

Revenue (Quarterly YoY Growth)

96.00%

Profit Margin

13.00%

Return on Equity

—

Debt to Equity Ratio

—

Dividend Yield

—

All fundamentals

Core5 fields›

Market Cap$38.46B

Revenue TTM$853.1M

Shares Outstanding2.67B

Insider Ownership0.00%

Institutional Ownership0.00%

Growth Estimates6 fields›

Revenue Growth (Quarterly YoY)96.00%

Rev Growth Est 1Y Forward0.3

EPS Growth (Quarterly YoY)0.00%

EPS Growth Est Quarterly0

CFO Growth (Quarterly YoY)-160.00%

FCF Growth (Quarterly YoY)-138.00%

Operations20 fields›

Revenue TTM$853.1M

Gross Margin TTM81.00%

Gross Margin (Quarterly)82.00%

Operating Margin TTM23.00%

Operating Margin (Quarterly)23.00%

Operating Expenses TTM$56.4M

Profit Margin TTM13.00%

Profit Margin (Quarterly)18.00%

Net Income TTM$100.0M

EPS TTM0.98

EPS (Quarterly)0.08

EBITDA Margin TTM19.00%

EBITDA TTM$160.6M

CFO % of Revenue TTM23.00%

CFO % of Revenue (Quarterly)6.00%

CFO TTM$197.1M

Capex % of Revenue TTM3.00%

Capital Expenditures$27.7M

FCF % of Revenue (Quarterly)11.00%

FCF TTM$127.6M

Efficiency1 fields›

ROA10.00%

Valuation11 fields›

P/E (TTM)384.74

P/E Forward33.44

PEG0.53

P/CFO195.12

P/FCF301.36

EV/Revenues (TTM)8.97

Price To Book179.73

Price to Tangible Book179.73

Earnings Yield0.00%

FCF Yield0.00%

Payout Ratio0.00%

Liquidity6 fields›

Cash Per Share21.97

Current Ratio2.76

Total Assets$1.02B

Total Liabilities$3.42B

Shareholders Equity$214.0M

Interest Expense$56.4M

Yields3 fields›

Payout Ratio0.00%

Earnings Yield0.00%

Buyback Yield2.00%